Fulgent Genetics vs Twist Bioscience
Twist Bioscience is the larger business, with $377m of revenue in fiscal 2025 against $323m for Fulgent Genetics (1.2 times as much). Twist Bioscience grew faster (20.3% against 13.8%). Fulgent Genetics kept more of each dollar of sales as profit: a net margin of -18.8% against -20.6%. Twist Bioscience carries less debt relative to equity (0.0% against 0.2%).
| Latest fiscal year | Fulgent GeneticsFLGT, 2025 | Twist BioscienceTWST, 2025 |
|---|---|---|
| Revenue | $323m | $377m |
| Revenue growth | 13.8% | 20.3% |
| Net income | −$60.5m | −$77.7m |
| Operating margin | -28.2% | -36.2% |
| Net margin | -18.8% | -20.6% |
| Return on equity | -5.4% | -16.4% |
| Free cash flow | −$124m | −$75.6m |
| Cash | $50.2m | $183m |
| Total debt | $2.4m | $0 |
| Debt to equity | 0.2% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $10.9m | — |
| Employees | — | 979 |
| Market value | $531m | $8.74bn |
| Price vs our value range | — | — |
| Moat score | 23 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 15 sales | 0 buys, 180 sales |